Interested in promotions? | Click here >>
PathScan® Total Fatty Acid Synthase Sandwich ELISA Kit

PathScan® Total Fatty Acid Synthase Sandwich ELISA Kit #7689

Citations (0)
No Current Image - PathScan® Total Fatty Acid Synthase Sandwich ELISA Kit
To Purchase # 7689

Important Ordering Details

Custom Ordering Details: When ordering five or more kits, please contact us for processing time and pricing at [email protected].

Supporting Data


Application Key:

  • W-Western
  • IP-Immunoprecipitation
  • IHC-Immunohistochemistry
  • ChIP-Chromatin Immunoprecipitation
  • IF-Immunofluorescence
  • F-Flow Cytometry
  • E-P-ELISA-Peptide

Species Cross-Reactivity Key:

  • H-Human
  • M-Mouse
  • R-Rat
  • Hm-Hamster
  • Mk-Monkey
  • Mi-Mink
  • C-Chicken
  • Dm-D. melanogaster
  • X-Xenopus
  • Z-Zebrafish
  • B-Bovine
  • Dg-Dog
  • Pg-Pig
  • Sc-S. cerevisiae
  • Ce-C. elegans
  • Hr-Horse
  • All-All Species Expected

Product Description

The PathScan® Total Fatty Acid Synthase Sandwich ELISA Kit is a solid phase sandwich enzyme-linked immunosorbent assay (ELISA) that detects endogenous levels of fatty acid synthase protein (FASN). A FASN Rabbit Antibody has been coated onto the microwells. After incubation with cell lysates, FASN is captured by the coated antibody. Following extensive washing, a biotinylated FASN Rabbit Detection Antibody is added to detect the captured FASN protein. HRP-linked streptavidin is then used to recognize the bound detection antibody. HRP substrate, TMB, is added to develop color. The magnitude of the absorbance for the developed color is proportional to the quantity of FASN.

Antibodies in kit are custom formulations specific to kit.

Specificity / Sensitivity

This kit detects proteins from the indicated species, as determined through in-house testing, but may also detect homologous proteins from other species.


Fatty acid synthase (FASN) catalyzes the synthesis of long-chain fatty acids from acetyl-CoA and malonyl-CoA. FASN is active as a homodimer with seven different catalytic activities and produces lipids in the liver for export to metabolically active tissues or storage in adipose tissue. In most other human tissues, FASN is minimally expressed since they rely on circulating fatty acids for new structural lipid synthesis (1).

According to the research literature, increased expression of FASN has emerged as a phenotype common to most human carcinomas. For example in breast cancer, immunohistochemical staining showed that the levels of FASN are directly related to the size of breast tumors (2). Research studies also showed that FASN is highly expressed in lung and prostate cancers and that FASN expression is an indicator of poor prognosis in breast and prostate cancer (3-5). Furthermore, inhibition of FASN is selectively cytotoxic to human cancer cells (5). Thus, increased interest has focused on FASN as a potential target for the diagnosis and treatment of cancer as well as metabolic syndrome (6,7).

  1. Katsurada, A. et al. (1990) Eur J Biochem 190, 427-33.
  2. Wells, W.A. et al. (2006) Breast Cancer Res Treat 98, 231-40.
  3. Kawamura, T. et al. (2005) Pathobiology 72, 233-240.
  4. Shah, U.S. et al. (2006) Hum Pathol 37, 401-409.
  5. Kuhajda, F.P. (2000) Nutrition 16, 202-8.
  6. Tian, W.X. (2006) Curr Med Chem 13, 967-977.
  7. Kusunoki, J. et al. (2006) Endocrine 29, 91-100.

Pathways & Proteins

Explore pathways + proteins related to this product.

For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
PathScan is a trademark of Cell Signaling Technology, Inc.